Creative Planning
MACK

Creative Planning’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Creative Planning’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-11,364
Closed -$111K – 4537
2017
Q2 		$111K Buy
11,364
+9,279
+445% +$190K ﹤0.01% 1918
2017
Q1 		$51K Sell
2,085
-687
-25% -$17.2K ﹤0.01% 2470
2016
Q4 		$89K Sell
2,772
-457
-14% -$19.5K ﹤0.01% 1951
2016
Q3 		$161K Buy
3,229
+2,141
+197% +$88.9K ﹤0.01% 1538
2016
Q2 		$46K Sell
1,088
-31
-3% -$1.69K ﹤0.01% 2193
2016
Q1 		$74K Buy
1,119
+63
+6% +$3.29K ﹤0.01% 1823
2015
Q4 		$66K Sell
1,056
-102
-9% -$7.18K ﹤0.01% 1897
2015
Q3 		$78K Buy
+1,158
New +$94.5K ﹤0.01% 1739
2015
Q2 		– Sell
-1,170
Closed -$109K – 3719
2015
Q1 		$109K Buy
1,170
+127
+12% +$10.8K ﹤0.01% 1534
2014
Q4 		$93K Buy
1,043
+254
+32% +$18.5K ﹤0.01% 1590
2014
Q3 		$55K Buy
789
+127
+19% +$6.79K ﹤0.01% 1864
2014
Q2 		$38K Hold
662
– – ﹤0.01% 2073
2014
Q1 		$26K Hold
662
– – ﹤0.01% 2231
2013
Q4 		$28K Hold
662
– – ﹤0.01% 2003
2013
Q3 		$20K Buy
+662
New +$23.2K ﹤0.01% 2116

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Creative Planning's MACK Position: Q3 2017 in Review

Creative Planning sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2017, closing a stake of 11,364 shares — an estimated $111K sold.

Creative Planning first reported a position in MACK in Q3 2013 and held it in 15 quarters. The position peaked at $161K in Q3 2016. 73 funds tracked by Wall St. Rank hold MACK as of Q3 2017.

  • Creative Planning reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Creative Planning sold 11,364 Merrimack Pharmaceuticals, Inc. shares in Q3 2017, an estimated $111K.
  • Creative Planning first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2013 and held it in 15 quarters.
  • Creative Planning's Merrimack Pharmaceuticals, Inc. position peaked at $161K in Q3 2016.
  • 73 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2017.

Based on Creative Planning's 13F filing for Q3 2017, filed 17 Oct 2017.